In a patient with coagulopathy, when should fresh‑frozen plasma be administered before a scheduled invasive procedure?

When to Give FFP Prior to Scheduled Procedure in Coagulopathy

For most scheduled bedside procedures (thoracentesis, paracentesis, central line placement), do not give FFP prophylactically regardless of INR elevation—the evidence shows no reduction in bleeding complications and significant risk of transfusion-related harm. 1

Procedure-Specific Approach

Low-Risk Procedures (DO NOT transfuse FFP)

• Central venous catheter placement
• Thoracentesis
• Paracentesis
• Chest tube insertion
• Image-guided drainage procedures

Rationale: The 2025 CHEST guidelines explicitly recommend against routine FFP transfusion for these procedures 1. Multiple studies demonstrate that bleeding complications are rare (0.2-6.75%) regardless of INR values, while FFP transfusion causes:

• Significant procedural delays (median 25.3 vs 16.4 hours) 2
• Volume overload in 13.8% of patients 3
• Transfusion reactions in 14.5% 2
• Acute lung injury risk 4
• Ineffective INR correction (only 7.9-32% achieve normalization) 2, 4

High-Risk Procedure (CONSIDER FFP transfusion)

• Lumbar puncture only

Target INR 1.5-2.0 before the procedure 1

Rationale: Lumbar puncture carries a 0.2% risk of devastating spinal hematoma when INR >1.4. While this risk is extremely low, the catastrophic consequences justify prophylactic correction 1.

Dosing When FFP Is Indicated

Administer 10-15 mL/kg (or dose calculated to achieve minimum 30% plasma factor concentration) 5

Critical caveat: Standard dosing fails to normalize INR in 68-92% of patients 2, 4. Each unit produces only 2.9% average INR decrease 2.

Timing Considerations

Administer FFP immediately before the procedure (within hours, not the day prior) since:

• Coagulation factors have short half-lives
• Delays in procedure increase morbidity, particularly for infected collections requiring drainage 2

When FFP Is Actually Indicated (per ASA guidelines) 5

• Active bleeding with documented coagulation factor deficiency
• Urgent warfarin reversal when PCCs unavailable
• Known specific factor deficiencies without available concentrates
• NOT indicated if PT/INR and aPTT are normal
• NOT indicated solely for volume expansion

Common Pitfalls to Avoid

1. Do not reflexively transfuse based on INR alone - INR elevation does not predict procedural bleeding risk for most bedside procedures 1, 6

2. Do not use inadequate doses - 53.8% of patients receive <10 mL/kg, which is clinically ineffective 7

3. Do not delay life-saving drainage procedures for FFP administration in infected collections—the mortality risk from delayed drainage exceeds bleeding risk 2

4. Do not assume FFP corrects coagulopathy - Only 32-54% achieve target INR reduction even with adequate dosing 4, 6

Alternative Strategies

For patients requiring actual correction (not prophylaxis):

• Prothrombin complex concentrates (PCCs) are superior to FFP for warfarin reversal 5
• Vitamin K1 provides better sustained correction when combined with FFP (mean INR reduction 1.32 vs 0.80 with FFP alone) 8
• Consider ultrasound guidance and experienced operators rather than prophylactic transfusion 1

Risk-Benefit Analysis

The evidence strongly favors withholding FFP for routine procedures because:

• Transfusion risks (volume overload, TRALI, reactions) are well-documented and frequent
• Bleeding prevention benefit is unproven
• Minor bleeding occurred in 9.3% of transfused vs 4.9% of non-transfused patients in one study 4
• No mortality difference between transfused and non-transfused groups 4, 6